ReviewDrug design, development and therapy2015

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?

Sai-Hong Ignatius Ou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.